交易 Virpax Pharmaceuticals, Inc. - VRPX CFD
加入收藏夹- 概括
- 历史数据
- 活动
- 收入报表
- 资产负债表
- 现金流
- 所有权
交易条件
价差 | 0.08 | ||||||||
多头隔夜费
Long position overnight fee
前往平台 | -0.025457% | ||||||||
空头隔夜费
Short position overnight fee
前往平台 | 0.003235% | ||||||||
隔夜费时间 | 21:00 (UTC) | ||||||||
最小交易量 | 1 | ||||||||
货币 | USD | ||||||||
保证金 | 20% | ||||||||
上市交易所 | United States of America | ||||||||
交易费 | 0% |
*Information provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | 平仓 | Change | Change (%) | 開倉 | High | Low |
---|---|---|---|---|---|---|
May 26, 2023 | 0.77 | -0.02 | -2.53% | 0.79 | 0.79 | 0.74 |
May 25, 2023 | 0.77 | 0.00 | 0.00% | 0.77 | 0.78 | 0.76 |
May 24, 2023 | 0.77 | 0.01 | 1.32% | 0.76 | 0.80 | 0.76 |
May 23, 2023 | 0.78 | -0.03 | -3.70% | 0.81 | 0.81 | 0.77 |
May 22, 2023 | 0.73 | 0.06 | 8.96% | 0.67 | 0.73 | 0.67 |
May 19, 2023 | 0.78 | -0.01 | -1.27% | 0.79 | 0.80 | 0.77 |
May 18, 2023 | 0.79 | -0.02 | -2.47% | 0.81 | 0.81 | 0.76 |
May 17, 2023 | 0.78 | 0.02 | 2.63% | 0.76 | 0.84 | 0.76 |
May 16, 2023 | 0.76 | -0.04 | -5.00% | 0.80 | 0.80 | 0.74 |
May 15, 2023 | 0.84 | -0.02 | -2.33% | 0.86 | 0.86 | 0.82 |
May 12, 2023 | 0.83 | 0.06 | 7.79% | 0.77 | 0.86 | 0.77 |
May 11, 2023 | 0.83 | 0.07 | 9.21% | 0.76 | 0.85 | 0.76 |
May 10, 2023 | 0.76 | -0.01 | -1.30% | 0.77 | 0.77 | 0.74 |
May 9, 2023 | 0.73 | -0.04 | -5.19% | 0.77 | 0.77 | 0.70 |
May 8, 2023 | 0.71 | 0.02 | 2.90% | 0.69 | 0.76 | 0.69 |
May 5, 2023 | 0.70 | 0.01 | 1.45% | 0.69 | 0.71 | 0.65 |
May 4, 2023 | 0.65 | -0.02 | -2.99% | 0.67 | 0.68 | 0.65 |
May 3, 2023 | 0.64 | 0.03 | 4.92% | 0.61 | 0.64 | 0.61 |
May 2, 2023 | 0.62 | -0.04 | -6.06% | 0.66 | 0.66 | 0.62 |
May 1, 2023 | 0.66 | 0.02 | 3.13% | 0.64 | 0.67 | 0.64 |
Virpax Pharmaceuticals, Inc. Events
时间(协调世界时) (UTC) | 国家/地区 | 事件 |
---|---|---|
No events scheduled |
- 年度
- 每季度
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
总收入 | 0 | 0 | 0 | 0 | 0 |
总营业费用 | 21.8451 | 12.0255 | 4.19572 | 3.18187 | 2.62596 |
销售/一般/行政费用,总计 | 11.0825 | 7.18639 | 2.9041 | 2.55913 | 1.48379 |
研究与开发 | 10.7627 | 4.83912 | 1.29162 | 0.62274 | 1.14218 |
营业收入 | -21.8451 | -12.0255 | -4.19572 | -3.18187 | -2.62596 |
利息收入(费用),非经营净值 | 0 | -0.09282 | -0.14793 | -0.12464 | -0.01498 |
税前净收入 | -21.6507 | -12.0561 | -4.33965 | -3.30651 | -2.64094 |
税后净收入 | -21.6507 | -12.0561 | -4.33965 | -3.30651 | -2.64094 |
未计算非常项目前的净收益 | -21.6507 | -12.0561 | -4.33965 | -3.30651 | -2.64094 |
净收入 | -21.6507 | -12.0561 | -4.33965 | -3.30651 | -2.64094 |
普通股股东可获收益 (不含非经常性项目) | -21.6507 | -12.0561 | -4.33965 | -3.30651 | -2.64094 |
普通股股东可获收益 (含非經常性項目) | -21.6507 | -12.0561 | -4.33965 | -3.30651 | -2.64094 |
摊薄净收入 | -21.6507 | -12.0561 | -4.33965 | -3.30651 | -2.64094 |
摊薄后加权平均股 | 11.7122 | 6.67727 | 4.94515 | 4.94515 | 4.94515 |
扣除特别项目的每股摊薄盈利 | -1.84856 | -1.80554 | -0.87756 | -0.66864 | -0.53405 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | ||
每股正常摊薄盈利 | -1.84856 | -1.80554 | -0.87756 | -0.66864 | -0.53405 |
其他,净值 | 0.19441 | 0.06226 | 0.004 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
总收入 | 0 | 0 | 0 | 0 | 0 |
总营业费用 | 1.65107 | 3.10208 | 7.71514 | 5.90409 | 5.12382 |
销售/一般/行政费用,总计 | 0.41545 | 1.74439 | 4.91004 | 2.64562 | 1.78241 |
研究与开发 | 1.23561 | 1.35769 | 2.8051 | 3.25847 | 3.34141 |
营业收入 | -1.65107 | -3.10208 | -7.71514 | -5.90409 | -5.12382 |
利息收入(费用),非经营净值 | 0 | 0 | 0 | 0 | |
税前净收入 | -1.52053 | -2.98711 | -7.64189 | -5.88472 | -5.137 |
税后净收入 | -1.52053 | -2.98711 | -7.64189 | -5.88472 | -5.137 |
未计算非常项目前的净收益 | -1.52053 | -2.98711 | -7.64189 | -5.88472 | -5.137 |
净收入 | -1.52053 | -2.98711 | -7.64189 | -5.88472 | -5.137 |
普通股股东可获收益 (不含非经常性项目) | -1.52053 | -2.98711 | -7.64189 | -5.88472 | -5.137 |
普通股股东可获收益 (含非經常性項目) | -1.52053 | -2.98711 | -7.64189 | -5.88472 | -5.137 |
摊薄净收入 | -1.52053 | -2.98711 | -7.64189 | -5.88472 | -5.137 |
摊薄后加权平均股 | 11.7143 | 11.7139 | 11.7134 | 11.7128 | 11.7087 |
扣除特别项目的每股摊薄盈利 | -0.1298 | -0.25501 | -0.65241 | -0.50242 | -0.43873 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
每股正常摊薄盈利 | -0.1298 | -0.25501 | -0.65241 | -0.50242 | -0.43873 |
其他,净值 | 0.13053 | 0.11497 | 0.07325 | 0.01937 | -0.01318 |
- 年度
- 每季度
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
流动资产总额 | 19.6737 | 39.5724 | 0.07307 | 0.04672 | 0.0615 |
现金和短期投资 | 18.9953 | 36.842 | 0.0548 | 0.04154 | 0.04837 |
Cash | 18.9953 | 36.842 | 0.0548 | 0.04154 | 0.04837 |
应收账款总额,净额 | 0 | 0.00139 | 0 | ||
Accounts Receivable - Trade, Net | 0 | 0.00139 | 0 | ||
Prepaid Expenses | 0.65302 | 2.61894 | 0.00879 | 0.0038 | 0.00263 |
Other Current Assets, Total | 0.02534 | 0.1115 | 0.00948 | 0 | 0.0105 |
Total Assets | 19.6737 | 39.5724 | 0.46541 | 0.04672 | 0.0615 |
Total Current Liabilities | 3.09459 | 2.08769 | 3.65991 | 2.77899 | 1.25422 |
Accrued Expenses | 0.65477 | 0.62728 | 0.27 | 0.81916 | 0.30572 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Port. of LT Debt/Capital Leases | 0 | 0.54399 | 1.26452 | 0.5 | |
Other Current Liabilities, Total | 2.43983 | 1.46041 | 2.84592 | 0.69531 | 0.44851 |
Total Liabilities | 3.09459 | 2.08769 | 4.6815 | 2.77899 | 1.25422 |
Total Long Term Debt | 0 | 0 | 1.02159 | 0 | 0 |
Total Equity | 16.5791 | 37.4847 | -4.2161 | -2.73228 | -1.19272 |
Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | 0 | 0 |
Common Stock | 0.00012 | 0.00012 | 0.00003 | 0.00015 | 0.00014 |
Additional Paid-In Capital | 60.9336 | 60.1885 | 6.43172 | 3.57577 | 1.80881 |
Retained Earnings (Accumulated Deficit) | -44.3546 | -22.7039 | -10.6478 | -6.30819 | -3.00168 |
Total Liabilities & Shareholders’ Equity | 19.6737 | 39.5724 | 0.46541 | 0.04672 | 0.0615 |
Total Common Shares Outstanding | 11.7143 | 11.7149 | 4.94515 | 4.94515 | 4.94515 |
Other Long Term Assets, Total | 0 | 0.39234 | |||
Long Term Debt | 0 | 1.02159 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
流动资产总额 | 18.4933 | 19.6737 | 23.6358 | 29.4024 | 34.746 |
现金和短期投资 | 16.9869 | 18.9953 | 20.5626 | 26.0611 | 30.7971 |
Cash | 16.9869 | 18.9953 | 20.5626 | 26.0611 | 30.7971 |
Prepaid Expenses | 1.47637 | 0.65302 | 3.04688 | 3.33408 | 3.81772 |
Other Current Assets, Total | 0.03006 | 0.02534 | 0.02627 | 0.00723 | 0.13112 |
Total Assets | 18.4933 | 19.6737 | 23.6358 | 29.4024 | 34.746 |
Other Long Term Assets, Total | |||||
Total Current Liabilities | 3.29424 | 3.09459 | 4.20787 | 2.48337 | 2.18689 |
Accrued Expenses | 0.16409 | 0.65477 | 0.31123 | 0.23561 | 0.15593 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Port. of LT Debt/Capital Leases | |||||
Other Current Liabilities, Total | 3.13015 | 2.43983 | 1.89664 | 2.24776 | 2.03096 |
Total Liabilities | 3.29424 | 3.09459 | 4.20787 | 2.48337 | 2.18689 |
Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
Long Term Debt | |||||
Total Equity | 15.1991 | 16.5791 | 19.4279 | 26.9191 | 32.5591 |
Preferred Stock - Non Redeemable, Net | 0 | 0 | |||
Common Stock | 0.00012 | 0.00012 | 0.00012 | 0.00012 | 0.00012 |
Additional Paid-In Capital | 61.0742 | 60.9336 | 60.7953 | 60.6446 | 60.3999 |
Retained Earnings (Accumulated Deficit) | -45.8752 | -44.3546 | -41.3675 | -33.7256 | -27.8409 |
Total Liabilities & Shareholders’ Equity | 18.4933 | 19.6737 | 23.6358 | 29.4024 | 34.746 |
Total Common Shares Outstanding | 11.7143 | 11.7143 | 11.7144 | 11.7146 | 11.7147 |
Payable/Accrued | 2 |
- 年度
- 每季度
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
净收入/起跑线 | -21.6507 | -12.0561 | -4.33965 | -3.30651 | -2.64094 |
经营活动产生的现金 | -17.8467 | -14.5426 | -1.38486 | -1.13183 | -1.79964 |
非现金物品 | 0.74503 | 0.91242 | 1.62686 | 1.24279 | 0.39993 |
Cash Taxes Paid | 0 | 0 | 0 | 0 | 0 |
已付现金利息 | 0 | 0.36282 | 0 | 0 | 0 |
营运资金的变化 | 3.05898 | -3.39895 | 1.32793 | 0.93189 | 0.44137 |
融资活动产生的现金 | 0 | 51.3298 | 1.39812 | 1.125 | 1.67477 |
股票的发行(报废),净额 | 0 | 58.02 | 1.3769 | 0.625 | 1.12 |
债务的发行(退还),净额 | 0 | -1.50376 | 0.0721 | 0.5 | 0.55477 |
现金净变化 | -17.8467 | 36.7872 | 0.01326 | -0.00683 | -0.12487 |
融资现金流项目 | 0 | -5.18645 | -0.05088 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Net income/Starting Line | -1.52053 | -21.6507 | -18.6636 | -11.0217 | -5.137 |
Cash From Operating Activities | -2.00837 | -17.8467 | -16.2794 | -10.7809 | -6.04486 |
Non-Cash Items | 0.14058 | 0.74503 | 0.60676 | 0.45604 | 0.21134 |
Cash Taxes Paid | 0 | 0 | 0 | 0 | 0 |
Cash Interest Paid | 0 | 0 | 0 | 0 | 0 |
Changes in Working Capital | -0.62842 | 3.05898 | 1.77747 | -0.21518 | -1.1192 |
Cash From Financing Activities | 0 | 0 | 0 | 0 | |
Financing Cash Flow Items | 0 | 0 | 0 | 0 | |
Issuance (Retirement) of Stock, Net | 0 | 0 | 0 | 0 | |
Issuance (Retirement) of Debt, Net | 0 | 0 | 0 | 0 | |
Net Change in Cash | -2.00837 | -17.8467 | -16.2794 | -10.7809 | -6.04486 |
投资者名称 | 投资者类型 | 流通股百分比 | 持有股份 | 股份变动 | 持有日期 | 换手率 |
---|---|---|---|---|---|---|
Virpax Pharmaceuticals LLC | Corporation | 23.3086 | 2730438 | 0 | 2023-03-22 | LOW |
Sabby Management, LLC | Investment Advisor/Hedge Fund | 5.988 | 701455 | -286710 | 2023-03-31 | LOW |
Mack (Anthony P.) | Individual Investor | 2.156 | 252562 | 0 | 2023-03-22 | LOW |
PNC Investments LLC | Investment Advisor | 0.8611 | 100875 | 0 | 2023-03-31 | LOW |
Renaissance Technologies LLC | Hedge Fund | 0.8135 | 95300 | -900 | 2023-03-31 | HIGH |
Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 0.5637 | 66038 | 0 | 2023-03-31 | LOW |
The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 0.5561 | 65145 | -112591 | 2023-03-31 | LOW |
Belpointe Asset Management LLC | Investment Advisor/Hedge Fund | 0.1626 | 19045 | 0 | 2023-03-31 | MED |
Warberg Asset Management LLC | Hedge Fund | 0.1452 | 17012 | 0 | 2023-03-31 | HIGH |
Cambridge Investment Research Advisors, Inc. | Investment Advisor | 0.1372 | 16070 | -400 | 2023-03-31 | LOW |
Northern Trust Investments, Inc. | Investment Advisor/Hedge Fund | 0.1299 | 15221 | 0 | 2023-03-31 | LOW |
Quantum Private Wealth, LLC | Investment Advisor | 0.0854 | 10000 | 0 | 2023-03-31 | LOW |
Sendrow (Jerrold B) | Individual Investor | 0.0769 | 9006 | 0 | 2023-03-22 | LOW |
Floyd (Eric) | Individual Investor | 0.0685 | 8023 | 5 | 2023-03-22 | LOW |
Gudin (Jeffrey) | Individual Investor | 0.0647 | 7584 | 0 | 2023-03-22 | LOW |
Tower Research Capital LLC | Hedge Fund | 0.0466 | 5463 | 333 | 2023-03-31 | HIGH |
Bruce (Gerald W) | Individual Investor | 0.0345 | 4045 | 0 | 2023-03-22 | LOW |
Advisor Group, Inc | Investment Advisor | 0.0051 | 600 | 0 | 2023-03-31 | LOW |
BlackRock Institutional Trust Company, N.A. | Investment Advisor | 0.004 | 464 | 0 | 2023-03-31 | LOW |
Morgan Stanley Smith Barney LLC | Investment Advisor | 0.0013 | 150 | -916 | 2023-03-31 | LOW |
交易计算器
如果您在特定日期(选择一个日期)开立差价合约交易并在不同日期(选择一个日期)关闭交易,计算您的假设盈亏。
交易佣金
0
- 1:1
杠杆
1:1
- 20
- 100
- 500
- 1000
- 10000
投资
交易规模(杠杆 x 投资):
開倉
平仓
做空 做多
Virpax Pharmaceuticals, Inc. Company profile
关于 Virpax Pharmaceuticals Inc
Virpax Pharmaceuticals, Inc.是一家处于临床前阶段的制药公司。 该公司专注于开发新型和专有的药物输送系统。 公司正在开发的药物输送系统和药物释放技术主要是为了推进非阿片类和非成瘾性疼痛管理治疗和中枢神经系统(CNS)疾病的治疗,以提高患者的生活质量。 公司的产品组合包括候选产品,如Epoladerm、Probudur、Envelta、PES200、AnQlar和VRP324。 Epoladerm是一种每日外用的非甾体抗炎药(NSAID),用于治疗膝关节慢性骨关节炎。 PES200能够将一种代谢不稳定的肽类药物(Enkephalin)送入大脑,用于治疗创伤后应激障碍。 AnQlar在体内研究中也显示了脑部病毒负荷的减少。 VRP324正在开发中,用于治疗两岁及以上患者的Dravet和Lennox-Gastaut综合症相关的癫痫发作。
Industry: | Biotechnology & Medical Research (NEC) |
1055 Westlakes Drive, Suite 300
BERWYN
PENNSYLVANIA 19312
US
收入报表
- Annual
- Quarterly
人们也观看
还在找一位您可以信任的经纪商吗?
加入成为全球530,000万多名交易者的一份子,选择利用Capital.com进行交易吧。